Transgene Biotek News

Transgene Biotek shuts trading window

Transgene Biotek Ltd closed its trading window from July 1, 2026, until 48 hours after Q1FY27 results are declared.

Transgene Biotek reports widened net loss in FY26

Transgene Biotek reported a net loss of ₹16.53 crore for FY26, widening from ₹6.76 crore in the previous year. Revenue from operations fell to ₹2.11 crore.

Transgene Biotek Confirms Non-Large Corporate Status

Transgene Biotek Limited confirms to BSE that it does not meet SEBI's Large Corporate criteria as per November 2018 circular, maintaining its classification outside the large entity category.

Transgene Biotek Files Non-Applicability Notice

Transgene Biotek Limited informed BSE that SEBI Regulation 32(1) requirements for Q4FY26 are not applicable as the company had no public or rights issues during the quarter ended March 31, 2026.

Transgene Biotek Confirms Non-Applicability of SEBI Reg

Transgene Biotek Limited informs BSE that SEBI LODR Regulation 57(5) is not applicable for Q4 FY26 as the company has not issued any non-convertible securities.